Female
M. Edwards, Hall, J., Williams, B., Johnson, L., and O'Bryant, S.,
“Molecular markers of amnestic mild cognitive impairment among Mexican Americans.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 221-8, 2016.
N. Voyle, Keohane, A., Newhouse, S., Lunnon, K., Johnston, C., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., Hodges, A., Kiddle, S., and Dobson, R. Jb,
“A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis.”,
J Alzheimers Dis, vol. 49, no. 3, pp. 659-69, 2016.
A. Koppara, Wolfsgruber, S., Kleineidam, L., Schmidtke, K., Frölich, L., Kurz, A., Schulz, S., Hampel, H., Heuser, I., Peters, O., Reischies, F. M., Jahn, H., Luckhaus, C., Hüll, M., Gertz, H. - J., Schröder, J., Pantel, J., Rienhoff, O., Rüther, E., Henn, F., Wiltfang, J., Maier, W., Jessen, F., Kornhuber, J., and Wagner, M.,
“The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”,
J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A.,
“APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”,
Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
J. C. Lambert, Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., DeStafano, A. L., Bis, J. C., Beecham, G. W., Grenier-Boley, B., Russo, G., Thorton-Wells, T. A., Jones, N., Smith, A. V., Chouraki, V., Thomas, C., Ikram, M. A., Zelenika, D., Vardarajan, B. N., Kamatani, Y., Lin, C. F., Gerrish, A., Schmidt, H., Kunkle, B., Dunstan, M. L., Ruiz, A., Bihoreau, M. T., Choi, S. H., Reitz, C., Pasquier, F., Cruchaga, C., Craig, D., Amin, N., Berr, C., Lopez, O. L., De Jager, P. L., Deramecourt, V., Johnston, J. A., Evans, D., Lovestone, S., Letenneur, L., Morón, F. J., Rubinsztein, D. C., Eiriksdottir, G., Sleegers, K., Goate, A. M., Fiévet, N., Huentelman, M. W., Gill, M., Brown, K., Kamboh, M. I., Keller, L., Barberger-Gateau, P., McGuiness, B., Larson, E. B., Green, R., Myers, A. J., Dufouil, C., Todd, S., Wallon, D., Love, S., Rogaeva, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., Lleo, A., Bayer, A., Tsuang, D. W., Yu, L., Tsolaki, M., Bossù, P., Spalletta, G., Proitsi, P., Collinge, J., Sorbi, S., Sanchez-Garcia, F., Fox, N. C., Hardy, J., Naranjo, M. C. Deniz, Bosco, P., Clarke, R., Brayne, C., Galimberti, D., Mancuso, M., Matthews, F., Moebus, S., Mecocci, P., Del Zompo, M., Maier, W., Hampel, H., Pilotto, A., Bullido, M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J. R., Mayhaus, M., Lannefelt, L., Hakonarson, H., Pichler, S., Carrasquillo, M. M., Ingelsson, M., Beekly, D., Alvarez, V., Zou, F., Valladares, O., Younkin, S. G., Coto, E., Hamilton-Nelson, K. L., Gu, W., Razquin, C., Pastor, P., Mateo, I., Owen, M. J., Faber, K. M., Jonsson, P. V., Combarros, O., O'Donovan, M. C., Cantwell, L. B., Soininen, H., Blacker, D., Mead, S., Mosley, T. H., Bennett, D. A., Harris, T. B., Fratiglioni, L., Holmes, C., de Bruijn, R. F., Passmore, P., Montine, T. J., Bettens, K., Rotter, J. I., Brice, A., Morgan, K., Foroud, T. M., Kukull, W. A., Hannequin, D., Powell, J. F., Nalls, M. A., Ritchie, K., Lunetta, K. L., Kauwe, J. S., Boerwinkle, E., Riemenschneider, M., Boada, M., Hiltuenen, M., Martin, E. R., Schmidt, R., Rujescu, D., Wang, L. S., Dartigues, J. F., Mayeux, R., Tzourio, C., Hofman, A., Nöthen, M. M., Graff, C., Psaty, B. M., Jones, L., Haines, J. L., Holmans, P. A., Lathrop, M., Pericak-Vance, M. A., Launer, L. J., Farrer, L. A., van Duijn, C. M., Van Broeckhoven, C., Moskvina, V., Seshadri, S., Williams, J., Schellenberg, G. D., and Amouyel, P.,
“Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”,
Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
R. C. Petersen, Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., Trojanowski, J. Q., and Weiner, M. W.,
“Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.”,
Neurology, vol. 74, no. 3, pp. 201-9, 2010.
C. R. Jack, Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., Roberts, R. O., Rocca, W. A., Boeve, B. F., and Petersen, R. C.,
“An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”,
Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
J. Li, Wang, Y. J., Zhang, M., Xu, Z. Q., Gao, C. Y., Fang, C. Q., Yan, J. C., and Zhou, H. D.,
“Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease.”,
Neurology, vol. 76, no. 17, pp. 1485-91, 2011.
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb,
“Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
M. D. Zwan, Villemagne, V. L., Doré, V., Buckley, R., Bourgeat, P., Veljanoski, R., Salvado, O., Williams, R., Margison, L., Rembach, A., S Macaulay, L., Martins, R., Ames, D., van der Flier, W. M., Ellis, K. A., Scheltens, P., Masters, C. L., and Rowe, C. C.,
“Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
K. Hoffmann, Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., Vestergaard, K., Brændgaard, H., Gottrup, H., Lolk, A., Wermuth, L., Jacobsen, S., Laugesen, L. P., Gergelyffy, R. G., Høgh, P., Bjerregaard, E., Andersen, B. B., Siersma, V., Johannsen, P., Cotman, C. W., Waldemar, G., and Hasselbalch, S. G.,
“Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial.”,
J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
K. Steenland, Goldstein, F. C., Levey, A., and Wharton, W.,
“A Meta-Analysis of Alzheimer's Disease Incidence and Prevalence Comparing African-Americans and Caucasians.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 71-6, 2016.
S. Baiardi, Capellari, S., Ladogana, A., Strumia, S., Santangelo, M., Pocchiari, M., and Parchi, P.,
“Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings.”,
J Alzheimers Dis, vol. 50, no. 2, pp. 465-76, 2016.
H. Hochstetler, Trzepacz, P. T., Wang, S., Yu, P., Case, M., Henley, D. B., Degenhardt, E., Leoutsakos, J. - M., and Lyketsos, C. G.,
“Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
C. E. Fischer, Qian, W., Schweizer, T. A., Millikin, C. P., Ismail, Z., Smith, E. E., Lix, L. M., Shelton, P., and Munoz, D. G.,
“Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 283-95, 2016.
A. Oulhaj, Jernerén, F., Refsum, H., A Smith, D., and de Jager, C. A.,
“Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment.”,
J Alzheimers Dis, vol. 50, no. 2, pp. 547-57, 2016.
M. Mapstone, Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., Nazar, M. D., Rich, S. A., Berlau, D. J., Peltz, C. B., Tan, M. T., Kawas, C. H., and Federoff, H. J.,
“Plasma phospholipids identify antecedent memory impairment in older adults.”,
Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R.,
“Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
G. W. Rebok, Ball, K., Guey, L. T., Jones, R. N., Kim, H. - Y., King, J. W., Marsiske, M., Morris, J. N., Tennstedt, S. L., Unverzagt, F. W., and Willis, S. L.,
“Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”,
J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
A. Bakker, Krauss, G. L., Albert, M. S., Speck, C. L., Jones, L. R., Stark, C. E., Yassa, M. A., Bassett, S. S., Shelton, A. L., and Gallagher, M.,
“Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.”,
Neuron, vol. 74, no. 3, pp. 467-74, 2012.
K. Talbot, Wang, H. - Y., Kazi, H., Han, L. - Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., Arvanitakis, Z., Schneider, J. A., Wolf, B. A., Bennett, D. A., Trojanowski, J. Q., and Arnold, S. E.,
“Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”,
J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
J. Zhou, Gennatas, E. D., Kramer, J. H., Miller, B. L., and Seeley, W. W.,
“Predicting regional neurodegeneration from the healthy brain functional connectome.”,
Neuron, vol. 73, no. 6, pp. 1216-27, 2012.
D. Head, Bugg, J. M., Goate, A. M., Fagan, A. M., Mintun, M. A., Benzinger, T., Holtzman, D. M., and Morris, J. C.,
“Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.”,
Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O.,
“Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”,
Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
